. Analytical data for ASOs. NA -not available 
ASO

Sequence and design (5'-3') MW calculated MW found UV purity Yield (mg)
CXCl12 mRNA in mouse liver from double MOP walk 
A-3W2 
GCATxGTTCTCACATTA
(2-49)
A-G2
GCATGxTTCTCACATTA
(5-39)
A-G3
GCATGTxTCTCACATTA
(3-38)
A-G4
GCATGTTxCTCACATTA
(4-27)
A-G5
GCATGTTCxTCACATTA
(6-20)
A-G6
GCATGTTCTxCACATTA
(2-10)
A-G7
GCATGTTCTCxACATTA
(2-15)
A-G8
GCATGTTCTCAxCATTA
(5-48)
A-G9
GCATGTTCTCACxATTA
(4-24)
A-G10 GCATGTTCTCACAxTTA 15 (6-43) Figure S4 . Activity of mono and di-MOP ASOs in primary hepatocytes after ASO treatment by by free uptake. A A-Cy3
A-CXC
A-G1 A-G2 A-G3 A-G4 A-G5 A-G6 A-G7 A-G8 A-G9 A-G10 A-5W1 A-5W2 A-5W3 A-3W1 A
A-G1 A-G2 A-G3 A-G4 A-G5 A-G6 A-G7 A-G8 A-G9 A-G10 A-5W1 A-5W2 A-5W3 A-3W1 A-3W2-CXC A-G1 A-G2 A-G3 A-G4 A-G5 A-G6 A-G7 A-G8 A-G9 A-G10 A-5W1 A-5W2 A-5W3 A-3W1 A-3W2
A5W1-Cy3
No ASO
ASO-Cy3
Sequence-Cy3
A-G2-Cy3 GCATGxTTCTCACATTA-Cy3 A-G3-Cy3 GCATGTxTCTCACATTA-Cy3 A-G4-Cy3 GCATGTTxCTCACATTA-Cy3 A-G9-Cy3 GCATGTTCTCACxATTA-Cy3
A-G2-Cy3
A-G3-Cy3
A-G4-Cy3
A-G9-Cy3 
ASO-Cy3 Sequence-Cy3
A-Cy3 GCATGTTCTCACATTA-Cy3 A-G1-Cy3 GCATxGTTCTCACATTA-Cy3 A-G2-Cy3 GCATGxTTCTCACATTA-Cy3 A-G3-Cy3 GCATGTxTCTCACATTA-Cy3 A-G4-Cy3 GCATGTTxCTCACATTA-Cy3 A-G9-Cy3 GCATGTTCTCACxATTA-Cy3
A-Cy3
A-G1-Cy3 A-G4-Cy3
A-G2-Cy3 A-G9-Cy3
A-CXC A-G1 A-G2 A-G3 A-G4 A-G5
A-G6 A-G7 A-G8 A-G9 A-G10 Figure S11 . Characterization of cleavage patterns (A and B) and initial rates (C) of MOP ASO/RNA duplexes after incubation with recombinant human RNaseH1. Site-specific insertion of a single MOP linkage produces profound changes in cleavage patterns by modulating key interactions with the enzyme while initial rates remain largely unaffected. A-G10 Slope = 6.7
A G1 G2 G3 G4 G5 G6 G7 G8 G9 G10
A B C
